Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Melbourne (Australia) and Bologna (Italy) – 13 September 2021. Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product Illuccix®
Telix is pleased to announce that it has entered into an exclusive commercial distribution agreement with Bologna-based Radius S.r.l. (Radius) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the Italian market. This agreement builds on the support Radius has provided Telix in distributing 68Ga-PSMA-11 for magisterial use in Italy.
Under the terms of the agreement, Radius will be the exclusive commercial distributor of Illuccix® in Italy for a period of three years from the national approval date. Radius is the market leader in the supply of gallium generators across Italy, a position which enables Radius to provide a secure supply of the 68Ga necessary for launching Illuccix®. Radius also has the advantage of being a supplier and service provider for cyclotrons and radiotherapy suites across Italy.
Radius CEO, Mauro Mei stated, “This commercial partnership with Telix will enable us to open the door to state-of-the-art PSMA imaging for the 39,000 men diagnosed with prostate cancer each year in Italy. Given that PSMA imaging represents the latest standard of care for prostate cancer imaging, having recently been included in European and U.S. clinical practice guidelines, we are delighted to be adding Illuccix® to our nuclear medicine portfolio and look forward to bringing this product to Italian men in need, upon receipt of regulatory approval.”
Telix EMEA President Richard Valeix added, “As we prepare for the European launch of Illuccix® we are pleased to have entered into this agreement with Radius. Italy is an important market and we look forward to working with Radius to bring this highly anticipated imaging agent to Italian men living with prostate cancer, once regulatory approval is received. Partnering with such a capable and patient-centric leader in nuclear medicine aligns with Telix’s mission of helping patients with cancer live longer, better quality lives.”
To read the full ASX disclosure please click here.
To return to Telix’s homepage please click here.